We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-1.15%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$2.35B
AUM Growth
-$748M
Cap. Flow
-$294M
Cap. Flow %
-12.51%
Top 10 Hldgs %
32.94%
Holding
108
New
18
Increased
28
Reduced
25
Closed
23

Top Buys

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$43.9M
2
CGEM icon
Cullinan Oncology
CGEM
+$33.2M
3
INCY icon
Incyte
INCY
+$30M
4
TMO icon
Thermo Fisher Scientific
TMO
+$24.9M
5
ARGX icon
argenx
ARGX
+$23.2M

Top Sells

Rank Stock Value
1
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$139M
2
ALGN icon
Align Technology
ALGN
+$62M
3
BSX icon
Boston Scientific
BSX
+$57.5M
4
LLY icon
Eli Lilly
LLY
+$54.5M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$46.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.8%
2 Technology 0.2%
3 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISRG icon
1
Intuitive Surgical
ISRG
$132B
$109M 4.63%
245,000
+19,000
+8% +$7.57M
BSX icon
2
Boston Scientific
BSX
$67.9B
$90.1M 3.83%
1,170,100
-785,900
-40% -$57.5M
NTRA icon
3
Natera
NTRA
$47B
$83M 3.53%
766,500
-36,800
-5% -$3.74M
ARVN icon
4
Arvinas
ARVN
$600M
$79.5M 3.38%
2,987,845
+2,655
+0.1% +$84.6K
ACHC icon
5
Acadia Healthcare
ACHC
$2.66B
$75.6M 3.21%
1,120,000
+115,000
+11% +$8.03M
DNTH icon
6
Dianthus Therapeutics
DNTH
$5.92B
$75.5M 3.21%
2,917,231
+199,677
+7% +$4.8M
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.74B
$68.5M 2.91%
3,335,000
+922,500
+38% +$19.3M
NBIX icon
8
Neurocrine Biosciences
NBIX
$15.7B
$67.6M 2.87%
491,000
-45,500
-8% -$6.24M
AVTR icon
9
Avantor
AVTR
$9.86B
$65.4M 2.78%
3,086,000
+391,000
+15% +$9.42M
CI icon
10
Cigna
CI
$73.7B
$61M 2.59%
184,500
– –
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.9B
$58.1M 2.47%
544,500
-39,500
-7% -$4.34M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$31.7B
$53.9M 2.29%
222,000
-21,000
-9% -$3.32M
REGN icon
13
Regeneron Pharmaceuticals
REGN
$81.8B
$50.4M 2.14%
48,000
-20,000
-29% -$19.4M
ILMN icon
14
Illumina
ILMN
$32.6B
$49.9M 2.12%
478,000
+905
+0.2% +$102K
THC icon
15
Tenet Healthcare
THC
$21.5B
$49.5M 2.1%
372,000
-229,000
-38% -$27.6M
ABBV icon
16
AbbVie
ABBV
$451B
$47.6M 2.02%
277,800
+50,800
+22% +$8.41M
TMO icon
17
Thermo Fisher Scientific
TMO
$230B
$44.2M 1.88%
80,000
+43,400
+119% +$24.9M
GPCR icon
18
Structure Therapeutics
GPCR
$3.38B
$42.2M 1.79%
1,075,000
+211,000
+24% +$8.66M
BPMC
19
DELISTED
Blueprint Medicines
BPMC
$41.3M 1.75%
383,000
-43,000
-10% -$4.3M
CGON icon
20
CG Oncology
CGON
$6.59B
$40.9M 1.74%
1,296,225
-158,540
-11% -$5.5M
MRK icon
21
Merck
MRK
$366B
$40.2M 1.71%
325,000
-177,000
-35% -$22.8M
RARE icon
22
Ultragenyx Pharmaceutical
RARE
$2.52B
$39.5M 1.68%
960,000
+26,500
+3% +$1.13M
IDYA icon
23
IDEAYA Biosciences
IDYA
$3.87B
$39.2M 1.67%
1,117,000
+317,300
+40% +$12.6M
DHR icon
24
Danaher
DHR
$152B
$37.5M 1.59%
150,000
+6,200
+4% +$1.57M
JANX icon
25
Janux Therapeutics
JANX
$1.1B
$35.2M 1.5%
840,219
+455,974
+119% +$21.4M
1
2 3 4 5

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q2 2024 Portfolio in Review

As of Q2 2024, Avidity Partners Management held 108 positions worth $2.35B, down 24% from $3.1B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $294M in Q2 2024, closing 23 positions and reducing 25 holdings. Its most notable exit was Fusion Pharmaceuticals Inc. Common Shares, an estimated $139M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Technology and Miscellaneous.

Against the trend, Avidity Partners Management opened a new position in Perspective Therapeutics worth $30.3M.

  • Avidity Partners Management's largest Q2 2024 buy was Perspective Therapeutics: 3,037,668 shares worth $30.3M.
  • Avidity Partners Management added most to Thermo Fisher Scientific in Q2 2024, an estimated $24.9M increase.
  • Avidity Partners Management's biggest Q2 2024 reduction was Boston Scientific, cutting an estimated $57.5M.
  • Avidity Partners Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $139M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $2.35B portfolio in Q2 2024.
  • Avidity Partners Management opened 18 new positions and closed 23 in Q2 2024.
  • Avidity Partners Management's portfolio value fell 24% quarter-over-quarter to $2.35B.

Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.